Now I have the full paper content. Let me carefully verify each reviewer claim against the actual text and tables before composing the final review.

**Verification notes:**

- **Table 1 accuracy check:** The harsh critic claims "EiNNs beats HG-DCM at 4-week US, 6-week US, 4-week Massachusetts, 6-week Massachusetts, and 8-week Massachusetts." This is wrong. From Table 1: HG-DCM wins US 2-wk, 6-wk, 8-wk; EiNNs wins US 4-wk; HG-DCM wins MA 2-wk, 4-wk, 8-wk; EiNNs wins MA 6-wk. HG-DCM wins 6/8, EiNNs wins 2/8. The specific list in the harsh critic is factually incorrect — removing the incorrect enumeration but keeping the valid underlying point that the comparison is narrow (2 locations).

- **Table 2 accuracy check:** Confirmed from the paper:
  - 4-week mean MAE: HG-DCM (110,452) >> CNN (11,238) — a 10× gap
  - 6-week median MAE: CNN (1,187.8) < HG-DCM (1,275.6) — CNN wins
  - 8-week median MAE: DELPHI (537.7) < HG-DCM (796.0) — DELPHI wins
  - The claim "CNN generally underperforms HG-DCM across all training horizons" (Section 3.2.2) is factually contradicted at 6-week median MAE.
  - The claim "HG-DCM consistently outperforms DELPHI across forecasting horizons" is contradicted at 8-week median MAE.

- **38.2% reduction at 2 weeks:** Verified: DELPHI 3609.1 → HG-DCM 2231.1, correct.

- **Cold-start framing concern:** Valid — Section 3.1.2 states HG-DCM uses "early-stage COVID-19" data from all 258 locations simultaneously during training. In a genuine cold-start, data from hundreds of locations of the same outbreak would not be available. This is a real tension, though the temporal constraint (2-8 weeks per location) does represent a kind of early-stage limitation.

- **β hyperparameter sensitivity:** Confirmed missing — α and β appear in Equations 3–5, but no values are stated in the paper body, and no sensitivity analysis is presented.

- **Wilcoxon test concern:** Verified — the paper uses this to show HG-DCM and DELPHI produce statistically different parameters (p<0.05), but two differently trained models will almost always produce different distributions. The interesting question — whether HG-DCM's estimates are more *calibrated* against known COVID-19 ranges — is not answered.

---

## Summary

HG-DCM is a framework for early-stage pandemic forecasting that pairs a residual CNN with the DELPHI compartmental model. The CNN is trained jointly on historical multi-disease data (Ebola, SARS, Dengue, Influenza) and early-stage COVID-19 data to predict DELPHI's 12 parameters, effectively regularizing parameter estimation when current-outbreak data is scarce. The paper additionally contributes a new multi-pandemic dataset spanning outbreaks since 1990.

## Strengths

- **Substantial median MAE improvement at the most policy-critical cold-start windows:** At 2 weeks of training data, HG-DCM reduces median MAE by 38.2% vs. DELPHI (3,609 → 2,231); at 4 weeks, by 32.4% (2,620 → 1,771). These improvements are calculated directly from Table 2 across 258 locations and represent real gains for the scenario the paper explicitly targets.

- **Dramatically fewer overshooting events:** Figure 4a quantifies overshooting (predicted final-week cumulative cases > 5× true) across all training-window lengths; HG-DCM and CNN have markedly fewer overshoot events than DELPHI. Figure 4b shows a concrete US 8-week case where DELPHI diverges sharply while HG-DCM tracks observed data, directly validating the regularization claim.

- **Novel multi-pandemic dataset:** The dataset covering COVID-19, Ebola, SARS, Dengue, and Influenza with aligned metadata (case time series + country indicators + epidemiological meta-data) addresses a documented data gap and enables the cross-disease transfer that is the paper's central contribution.

- **Architecturally well-motivated modification:** Removal of Batch Normalization from the ResNet to avoid instability when batches mix historically distinct pandemics (Section 2.1) is a concrete, reasoned design choice grounded in the cross-disease transfer setting.

## Weaknesses

### Fatal
None. The core approach is coherent and the primary claim (historical transfer improves 2–4 week median MAE across 258 locations) is supported by Table 2.

### Major

- **Selective and inaccurate characterization of Table 2.** The paper states "HG-DCM consistently outperforms DELPHI across forecasting horizons" (Section 3.2.2), but at 8-week median MAE, DELPHI (537.7) outperforms HG-DCM (796.0) by a substantial margin. Similarly, "CNN generally underperforms HG-DCM across all training horizons" is falsified at 6-week median MAE, where CNN (1,187.8) beats HG-DCM (1,275.6). These are direct misstatements about the paper's own table, not framing differences, and they affect a reader's ability to calibrate the method's true strengths.

- **Large mean MAE spike at 4-week window.** At 4-week mean MAE, HG-DCM (110,452) is nearly 10× worse than CNN (11,238) and exceeds T-DCM (17,691) by 6×. This is the precise window — 4 weeks into an outbreak — where policy decisions are most consequential. The authors attribute this to overshooting events inflating the mean, but overshooting *is* the core problem the paper claims to solve. The paper does not provide a breakdown of how many locations are driving this spike or what the performance is excluding overshoot cases; it is presented in a section focused on median MAE without direct comment on this cell.

- **Table 1 external comparison covers only 2 locations (US and Massachusetts) with sparse population of cells.** The paper explicitly states this is because "they were the only locations in which there was available data and code for the comparison methods" (Section 3.2.1). HG-DCM wins 6 of 8 available cells (US 4-week goes to EiNNs; MA 6-week goes to EiNNs). While the limitation is acknowledged, the abstract and introduction make broad comparative claims that a 2-location, partially-populated table cannot support. Wider evaluation against GradABM or EiNNs is needed for the comparative claims to hold.

### Minor

- **The training setup only partially matches the cold-start motivating scenario.** HG-DCM is trained on early-stage COVID-19 data from all 258 locations simultaneously (Section 3.1.2, Equation 4). In a true cold-start for a completely novel pathogen, a researcher would have data from very few or no current-outbreak locations. The paper's evaluation reflects temporal early-stage scarcity (2–8 weeks per location) but not geographic cold-start. The distinction matters for evaluating generalizability — a leave-region-out evaluation would more directly test the paper's central motivation.

- **Key hyperparameters α and β are unreported and untested.** β controls the balance between historical and current pandemic loss (Equation 5), making it arguably the most sensitive hyperparameter in the entire framework. α balances MAE vs. MAPE. Neither value is reported anywhere in the paper body, and there is no sensitivity analysis. For a paper whose central claim is that historical guidance provides useful regularization, robustness to β is directly germane.

- **T-DCM ablation design is underspecified.** The paper states T-DCM "excluded historical pandemic data and meta-data... trained on datasets with 2, 4, 6, or 8 weeks of observations" (Section 3.2.2). It is unclear whether T-DCM uses the same ResNet architecture as HG-DCM but trained from random initialization on tiny current-pandemic data only. If so, the performance gap partly reflects the impossibility of training a deep ResNet on a few weeks of noisy data — a known limitation independent of the historical-transfer hypothesis. The ablation is informative but conflates two effects.

### Trivial

- The paper says the Wilcoxon test showing "significant differences in all parameters (p < 0.05)" between HG-DCM and DELPHI demonstrates that HG-DCM produces "more conservative and realistic estimates" (Section 3.2.3). Statistical difference between two differently trained models is nearly guaranteed; it does not establish that HG-DCM's estimates are better-calibrated. The parameter comparison is suggestive but the conclusion overstates what the test demonstrates.

## Nice-to-Haves

- **Disease-source ablation (leave-one-disease-out):** Training HG-DCM without each historical disease source (e.g., without Dengue, without Influenza) would reveal which diseases drive the improvement — an important mechanistic test given the biological diversity of the training set.
- **Honest re-framing of Table 2 narrative:** The honest story in Table 2 is compelling on its own terms: HG-DCM's advantage peaks at 2–4 weeks (where historical guidance matters most) and attenuates as the outbreak matures. Framing this honestly — *the advantage is strongest precisely when it is most needed* — is more credible than asserting universal dominance.
- **β sensitivity analysis:** Even a simple 3-point sweep of β would substantially strengthen the claim that historical transfer is robust rather than requiring careful calibration.
- **Confidence intervals or variance estimates on Table 2:** The large mean/median divergence at several cells signals high variance across locations; variance estimates would enable more principled comparison.

## Removed Points

*These points are flagged to be removed; treat them with caution.*

- **Harsh critic's enumeration of Table 1 losses**: "EiNNs beats HG-DCM at 4-week US, 6-week US, 4-week Massachusetts, 6-week Massachusetts, and 8-week Massachusetts." This is factually wrong — from the table, EiNNs beats HG-DCM in only 2 cells (US 4-week, MA 6-week). The underlying concern (comparison is narrow) is valid and is retained, but the specific error count is removed.

- **T-DCM unfairness as "not a valid test"**: The harsh critic argues T-DCM is not a valid ablation. This is demoted to Minor because the concern is valid in principle but cannot be confirmed fatal without appendix details about T-DCM's architecture initialization (stripped from the document).

- **"First study" novelty claim insufficiently rigorous**: The critic notes the distinction between "multiple prior pandemics" and prior work is quantitative, not qualitative. This is true but is a philosophical claim about degree of novelty — not a specific error anchored to a sentence/table.

- **Missing held-out location cross-validation as a fatal flaw**: The critic calls the lack of leave-region-out evaluation "structural." While it would strengthen the paper significantly, the current evaluation (early temporal windows across 258 locations) is a valid way to test the stated method under its stated framing. This is moved to Nice-to-Have.

- **Strength Finder claim that EiNNs outperformance is "majority" of cells**: The strength finder states HG-DCM "outperforms both GradABM and EiNNs in the majority of U.S./Massachusetts settings." This is correct (6 of 8 cells) and retained, but the framing requires noting the 2 losses.

- **Wilcoxon statistical test as a "strength"**: Moved from strength to trivial-level weakness as noted above.

## Novel Insights

The paper's most underemphasized finding — visible in Table 2 but not named — is that HG-DCM's advantage is *asymmetric across time*: it is strongest at 2–4 weeks (median MAE −38% and −32% vs. DELPHI) and diminishes as more COVID data accumulates, with DELPHI even overtaking at 8-week median MAE. This is a coherent and mechanistically interpretable story: historical transfer acts as a prior that stabilizes estimation when the likelihood surface is flat (too little data), but adds bias relative to a flexible optimizer once the current-outbreak signal is rich enough to dominate. Explicitly characterizing this "prior-dominance to likelihood-dominance transition" as a function of training window length would represent a genuinely new conceptual contribution to the transfer-learning-for-epidemiology literature, but the paper currently papers over this arc in favor of claiming uniform superiority.

## Suggestions

1. Correct the factual misstatements in Section 3.2.2: DELPHI outperforms HG-DCM at 8-week median MAE; CNN outperforms HG-DCM at 6-week median MAE. These should be acknowledged and explained rather than obscured.
2. Provide α and β values used in all experiments, and include at minimum a 3-point sensitivity sweep for β.
3. Add a brief breakdown of the 4-week mean MAE spike: how many locations are experiencing overshooting events at 4 weeks, and what is the HG-DCM mean MAE excluding those locations? This is essential context for a reader trying to decide whether to deploy the method.
4. Consider a leave-region-out experiment (e.g., train on historical + early-COVID from non-US locations, evaluate on US) to directly address the cold-start generalization claim.

---

**Axis evaluation:**
- *Originality:* Moderately novel — cross-disease temporal transfer for compartmental model regularization has not been systematically done before; the multi-pandemic dataset is new.
- *Importance:* High — early pandemic forecasting with scarce data is a genuine and important problem.
- *Claims supported:* Partially — the 2–4 week median MAE claim is well-supported; "consistent outperformance" is not.
- *Soundness of experiments:* Moderate — 258-location ablation is solid; Table 1 external comparison is thin; T-DCM design is underspecified; key hyperparameters unreported.
- *Clarity of writing:* Good overall, but the Results section contains verifiable inaccuracies in characterizing Table 2.
- *Value to community:* Moderate-to-high — the dataset alone is a contribution; the method is practical and interpretable.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>

<subscores>
<originality>3</originality>
<importance>4</importance>
<claims_supported>2</claims_supported>
<soundness>2</soundness>
<clarity>3</clarity>
<community_value>3</community_value>
</subscores>